IPCA Laboratories

IPCA Laboratories Net Debt

The Net Debt of IPCA Laboratories (IPCALAB.NS) as of Oct 31, 2026 is 1.09 B INR. In the previous year, Net Debt was -156.60 M INR — a change of -796.81% (higher).

Net Debt

1.09 BINR

YoY

-796.81%

Last updated:

Net Debt of IPCA Laboratories is 2026 1.09 B INR. Net Debt of IPCA Laboratories was 2025 -156.60 M INR. It decreases by -796.81% higher compared to the previous year.

The IPCA Laboratories Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2019
-210.20 M INR
Jan 1, 2020
87.10 M INR
Jan 1, 2021
-5.75 B INR
Jan 1, 2022
-5.96 B INR
Jan 1, 2023
-8.57 B INR
Jan 1, 2024
3.34 B INR
Jan 1, 2025
-156.60 M INR
Jan 1, 2026
1.09 B INR
The IPCA Laboratories Net Debt history
YEARNet DebtYoY
1.09 BINR-796.81%
-156.60 MINR-104.69%
3.34 BINR-139.01%
-8.57 BINR+43.85%
-5.96 BINR+3.61%
-5.75 BINR-6,699.54%
87.10 MINR-141.44%
-210.20 MINR-108.26%
2.54 BINR-34.10%
3.86 BINR-22.83%
5.00 BINR-65.22%
14.38 BINR+60.41%
8.97 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IPCA Laboratories Stock analysis

What does IPCA Laboratories do? Ipca Laboratories Ltd. generates revenue through the manufacturing and marketing of over 350 pharmaceutical formulations and approximately 80 active pharmaceutical ingredients (APIs), including Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts, and Propranolol. The company sells its branded products such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, and Venpower in more than 100 countries globally. Its subsidiaries, Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd, and Tonira Exports Limited, support the distribution and sales of these products across international markets. The company's primary customers are healthcare providers, hospitals, and pharmacies in over 100 countries, purchasing both generic APIs and branded formulations. Manufacturing units in India produce APIs and formulations, with the firm's subsidiaries facilitating global market access. The therapeutic segments covered by its products include cardiovascular, antimalarial, and gastrointestinal treatments, among others, driven by the demand for cost-effective pharmaceutical solutions. IPCA Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IPCA Laboratories stock

Net Debt of IPCA Laboratories is 1.09 B INR in 2026.

Net Debt of IPCA Laboratories changed from -156.60 M INR to 1.09 B INR, representing a -796.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt IPCA Laboratories since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's IPCA Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — IPCA Laboratories

All Key Metrics — IPCA Laboratories